IBgard® is a medical food specially formulated for the dietary management of IBS. IBgard® capsules contain individually triple-coated, sustained-release microspheres of Ultramen®, an ultra-purified peppermint oil. In a recent clinical study, IBgard® has been shown to start working in as early as 24 hours*. IBgard® can help to...
- Normalize 1 digestion of food and absorption of nutrients that have been compromised by IBS
- Manage the accompanying and often distressing symptoms of IBS including abdominal pain, bloating, diarrhea, constipation, urgency, gas, pain at evacuation, and a sense of an incomplete bowel movement.
- Promote 2 bacterial balance in the small intestine (part of the lower gut)
The IBgard® Difference - Advanced Science
Peppermint oil, the primary ingredient in IBgard®, is used for its utility in IBS. However, until now, its targeted delivery to the small intestine (part of the lower gut) had posed a challenge. IBgard® uses the precision of SST® (Site Specific Targeting) technology. This technology delivers microspheres of peppermint oil quickly and reliably where they are needed the most in IBS – predominantly in the small intestine. IBgard® helps normalize the digestive system, which enables proper digestion of food and enhances the absorption of nutrients.
Why Targeting to the Small Intestine is So Important
The symptoms of IBS often occur within 90 minutes of eating. This reflects the time it takes for food to reach the small intestine. Recent scientific and clinical evidence points to the small intestine as the site of the disturbance in IBS, where transit time is disrupted and food moves too fast or too slow causing diarrhea, constipation or both. This is also the site where gas is trapped and abdominal pain originates. Only IBgard® utilizes SST® (Site Specific Targeting) technology to deliver its ingredients to the small intestine. IBgard® has been specially formulated so that it can be taken 30 minutes before or after eating to provide its calming properties.
1 Goerg, K.J. et al., Aliment Pharmacol Ther 2003; 17:445-451.
2 Hawrelak, J.A. et al,. Alternative Medicine Review Vol 14, #4 2009, pg. 380-384.